Literature DB >> 2888532

Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells.

W T Beck1, M C Cirtain, M K Danks, R L Felsted, A R Safa, J S Wolverton, D P Suttle, J M Trent.   

Abstract

We previously described the cross-resistance patterns and cellular pharmacology of a human leukemic cell line, CEM/VM-1, selected for resistance to the epipodophyllotoxin teniposide (M. K. Danks et al., Cancer Res., 47: 1297-1301, 1987). Compared to CEM/VLB100, which is a well characterized "classic" multidrug-resistant (MDR) cell line, the CEM/VM-1 cells display "atypical" multidrug resistance (at-MDR) in that they are cross-resistant to a wide variety of natural product antitumor drugs, except the Vinca alkaloids, and they are not impaired in their ability to accumulate radiolabeled epipodophyllotoxin. We have extended our characterization of this at-MDR cell line in the present study. In comparison to CEM/VLB100 cells, we found that CEM/VM-1 cells are not cross-resistant to either actinomycin D or colchicine. Verapamil and chloroquine, which enhance the cytotoxicity of vinblastine in CEM/VLB100 cells, had little or no ability to do so in the CEM/VM-1 cells. Membrane vesicles of the two resistant sublines were examined for overexpression of the MDR-associated plasma membrane protein (P-glycoprotein, Mr 170,000 protein, or 180,000 glycoprotein) by photoaffinity labeling with the vinblastine analogue N-(p-azido[3-125I]salicyl)-N'-beta-aminoethylvindesine. We were unable to visualize the MDR-associated protein in the CEM/VM-1 membranes with this photoaffinity probe under conditions in which the P-glycoprotein was readily seen in the membranes of CEM/VLB100 cells. Furthermore, no hybridization of the pMDR1 complementary DNA was seen in slot-blot analyses of the RNA from at-MDR cells, indicating that the mdr gene coding for P-glycoprotein is not overexpressed as is the case in the classic MDR cells. However, cytogenetic analysis indicated that the CEM/VM-1 cells contained an abnormally banded region on chromosome 13q, suggesting that a gene other than mdr may be amplified in these cells. Thus, despite the two cell lines having approximately equal degrees of resistance to epipodophyllotoxins, our data indicate that the mechanism(s) responsible for at-MDR is different from that for classic, P-glycoprotein-associated MDR.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2888532

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  45 in total

1.  Evaluation of an in vitro coculture model for the blood-brain barrier: comparison of human umbilical vein endothelial cells (ECV304) and rat glioma cells (C6) from two commercial sources.

Authors:  J L Scism; D A Laska; J W Horn; J L Gimple; S E Pratt; R L Shepard; A H Dantzig; S A Wrighton
Journal:  In Vitro Cell Dev Biol Anim       Date:  1999 Nov-Dec       Impact factor: 2.416

Review 2.  Drug resistance in oncology: from concepts to applications.

Authors:  J L Cazin; P Gosselin; P Cappelaere; J Robert; A Demaille
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

3.  Association of sorcin with drug resistance in L1210 cells.

Authors:  D Roberts; M B Meyers; J L Biedler; L G Wiggins
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  In vivo etoposide-resistant C6 glioma cell line: significance of altered DNA topoisomerase II activity in multi-drug resistance.

Authors:  T Taki; T Ohnishi; N Arita; S Hiraga; T Hayakawa
Journal:  J Neurooncol       Date:  1998-01       Impact factor: 4.130

Review 5.  Altered DNA topoisomerase II in multidrug resistance.

Authors:  W T Beck; M K Danks; J S Wolverton; B Granzen; M Chen; C A Schmidt; B Y Bugg; E Friche; D P Suttle
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

Review 6.  Topoisomerase I in multiple drug resistance.

Authors:  A Pessina
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

7.  Pharmacological and molecular characterization of intrinsic and acquired doxorubicin resistance in murine tumor cell lines.

Authors:  B Schott; D Londos-Gagliardi; C Ries; S Huet; J Robert
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

8.  Novel carbamate analogues of amsacrine with activity against non-cycling murine and human tumour cells.

Authors:  G J Finlay; K M Holdaway; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

9.  Topoisomerase II alpha expression and the benefit of adjuvant chemotherapy for postoperative patients with non-small cell lung cancer.

Authors:  Shi Yan; Jiao Shun-Chang; Chen Li; Li Jie; Lv Ya-Li; Wang Ling-Xiong
Journal:  BMC Cancer       Date:  2010-11-10       Impact factor: 4.430

10.  Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide.

Authors:  B Y Bugg; M K Danks; W T Beck; D P Suttle
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.